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Les déterminants génétiques des effets secondaires
métaboliques induits par la clozapine

Kamini Vasudev, MBBS, MD, DNB, MRCPsych1, Yun-Hee Choi, PhD2,
Ross Norman, PhD, CPsych3, Richard B. Kim, MD, FRCPC4,
and Ute I. Schwarz, MD, PhD4

Abstract
Objective: Atypical antipychotics are linked to a higher incidence of metabolic side effects, including weight gain, dyslipidemia,
and diabetes. In this study, we examined the prevalence and potential genetic predictors of metabolic side effects in 60 adult
patients on clozapine.
Method: Genetic variants of relevance to clozapine metabolism, clearance, and response were assessed through targeted
genotyping of cytochrome P450 enzymes CYP1A2 and CYP2C19, the efflux transporter ABCB1, the serotonin receptor
(HTR2C), leptin (LEP), and leptin receptor (LEPR). Clozapine levels and other potential confounders, including concurrent
medications, were also included in the analysis.
Results: More than half of the patients were obese (51%), had metabolic syndrome (52.5%), and 30.5% were overweight.
There was a high prevalence of antipsychotic polypharmacy (61.9%). With multivariable linear regression analysis, LEP –
2548G>A, LEPR c.668A>G, and HTR2C c.551-3008 C>G were identified as genetic predictors of body mass index (BMI) after
considering effects of clozapine dose, blood level, and concurrent medications (adjusted R2 ¼ 0.305). Metabolic syndrome was
found to be significantly associated with clozapine level and CYP2C19*2 and LEPR c.668 G alleles. Clozapine levels in patients
with metabolic syndrome were significantly higher compared to those without metabolic syndrome (1886 + 895 vs. 1283 +
985 ng/mL, P < 0.01) and were associated with the CYP2C19*2 genotype. No association was found between the genetic
variants studied and lipid or glucose levels.
Conclusion: This study confirms a high prevalence of metabolic side effects with clozapine and suggests higher clozapine level
and pharmacogenetic markers in CYP2C19, LEP, LEPR, and HTR2C receptors as important predictors of BMI and metabolic
syndrome.
Abrégé
Objectif : Lea antipsychotiques atypiques sont liés à une incidence accrue d’effets secondaires métaboliques, dont la prise de
poids, la dyslipidémie et le diabète. Dans cette étude, nous avons examiné la prévalence et les prédicteurs génétiques
potentiels des effets secondaires métaboliques chez 60 patients adultes traités par clozapine.
Méthode : Les variantes génétiques se rapportant au métabolisme, à la clairance et à la réponse de la clozapine ont été
évaluées par le génotypage ciblé des enzymes CYP1A2, CYP2C19 du cytochrome P450, du transporteur d’efflux ABCB1, du

1
2
3
4

Departments of Psychiatry and Medicine, Western University, London, Ontario
Department of Epidemiology and Biostatistics, Western University, London, Ontario
Department of Psychiatry and Epidemiology and Biostatistics, Western University, London, Ontario
Department of Medicine, Physiology & Pharmacology, and Oncology, Western University, London, Ontario

Corresponding Author:
Kamini Vasudev, MBBS, MD, DNB, MRCPsych, A2-513, Victoria Hospital, London Health Sciences Centre, London, ON N6A 5W9, Canada.
Email: Kamini.vasudev@lhsc.on.ca

La Revue Canadienne de Psychiatrie 62(2)

139

récepteur de la sérotonine (HTR2C), de la leptine (LEP) et du récepteur de la leptine (LEPR). Les taux de clozapine et d’autres
facteurs de confusion potentiels, y compris les médicaments concurrents, étaient aussi inclus dans l’analyse.
Résultats : Plus de la moitié des patients étaient obèses (51%), souffrant d’un syndrome métabolique (52,5%), et 30,5%
avaient un excédent de poids. Il y avait une prévalence élevée de polypharmacie antipyschotique (61,9%). À l’aide de l’analyse
de régression linéaire multivariable, LEP -2548G>A, LEPR c.668A>G et HTR2C c.551-3008 C>G ont été identifiés comme
étant des prédicteurs génétiques de l’indice de masse corporelle (IMC) après examen des effets de la dose et de la concentration sanguine de la clozapine, et des médicaments concurrents (ajust. R2 0,305). Le syndrome métabolique s’est révélé
être associé significativement au taux de clozapine, ainsi qu’aux allèles CYP2C19*2 et LEPR c.668 G. Les taux de clozapine chez
les patients souffrant d’un syndrome métabolique étaient significativement plus élevés que chez les patients sans syndrome
métabolique (1886 + 895 c. 1283 + 985 ng/mL, p < 0,01) et étaient associés au génotype CYP2C19*2. Aucune association n’a
été obervée entre les variantes génétiques étudiées et les taux de glucose ou de lipides.
Conclusion : Cette étude confirme la prévalence élevée d’effets secondaires métaboliques de la clozapine et suggère que le
taux élevé de clozapine et les marqueurs pharmacogénétiques dans CYP2C19, LEP, LEPR et les récepteurs HTR2C soient
d’importants prédicteurs de l’IMC et du syndrome métabolique.
Keywords
clozapine, metabolism, pharmacogenetics, pharmacokinetics

Clinical Implications
 Pharmacogenetic markers in LEP, LEPR, and HTR2C
receptors are important predictors of body mass index
in patients on clozapine.
 Education is needed to reduce antipsychotic polypharmacy, particularly with clozapine.
 Clinicians should use clozapine levels as a tool to
monitor for risk of metabolic syndrome.

Limitations
 The study was cross-sectional in nature and had a
relatively small sample size.
 Larger controlled prospective studies are warranted to
confirm clinical implications of the genetic risk factors identified in this study.

Introduction
Schizophrenia is a severe mental illness and is associated
with mortality rates 2 to 3 times higher than the general
population.1 Schizophrenia has been reported as an independent risk factor for metabolic syndrome, including insulin
resistance and increased visceral adiposity.2,3 Several studies
now confirm that increased risk of mortality in schizophrenia
is attributable to unhealthy lifestyle and physical illnesses,
with cardiovascular disease (CVD) being the major
contributor.4,5
Atypical antipsychotics are currently the first-line treatment options for schizophrenia and other psychotic illnesses.
These are preferred over the typical antipsychotics due to the
decreased incidence of extrapyramidal side effects. However, atypical antipsychotics such as clozapine, olanzapine,
risperidone, and quetiapine are associated with varying

degrees of metabolic side effects, including weight gain,
diabetes mellitus, and dyslipidemia, thereby further increasing the metabolic and cardiovascular (CV) risks in patients
treated with such agents.6,7 Among those, clozapine and
olanzapine are reported to carry the highest risk for metabolic side effects.8,9 Clozapine, not preferred as a first-line
agent due to the risk of a serious though rare side effect of
neutropenia, is the only antipsychotic reserved for treatmentresistant schizophrenia. Significant improvement has been
observed in 30% to 60% of such patients when switched to
clozapine treatment.10 Unfortunately, almost half of the individuals on clozapine develop metabolic side effects over the
course of therapy.11
Considerable variability has been reported in the incidence of metabolic side effects among patients prescribed
atypical antipsychotics. This may result from differences in
the drugs’ pharmacokinetics (drug metabolism and transport
affecting systemic drug exposure) and pharmacodynamics
(pharmacological action) that are influenced by genetic factors.12 Clozapine acts as antagonist of dopamine (D2 and
D4) and serotonin (5HT2 and 3) receptors, as well as adrenergic, cholinergic, and histamine (H) 1 receptors. Antagonistic drug effects at the H1 and serotonin 2C subtype
receptor (HTR2C) have been implicated in weight gain as
well as obesity-independent diabetes.13 Two meta-analyses
reported an association of HTR2C genotype (rs3813929)
with antipsychotic-induced weight gain.14,15 There is also
evidence that the metabolic effects of atypical antipsychotics
may be mediated by peptide hormone regulators of metabolic control, including leptin and ghrelin.16 To date, associations of gene polymorphisms in 5HTR2C (rs3813929,
rs1414334) as well as leptin (LEP; rs7799039) and leptin
receptor (LEPR; rs1137101) with antipsychotic-induced
weight gain and metabolic syndrome have been widely
reported yet with varying results, and sex-specific effects
have been postulated by some.14,17-22 Furthermore, leptin
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has also been suggested to increase blood pressure through
sympathetic activation in the circulatory system or at the
renal level,23 and LEP gene polymorphisms as well as leptin
plasma levels were shown to correlate with blood pressure,
particularly in women.24,25
Clozapine is predominantly metabolized by cytochrome
P450 (CYP) 1A2 to its active metabolite norclozapine (also
N-desmethylclozapine), whereas CYP2C19, CYP2D6, and
CYP3A4 are thought to represent minor deactivating pathways.26,27 Norclozapine exposure is reported to be about
50% to 70% of that of the parent compound with similar
affinity to D2 and 5HT2 receptors.27 In a recent study,
impaired-function polymorphisms in CYP1A2 (*1C; *1D)
were associated with higher serum clozapine concentration
but also increased insulin and lipid levels in a small set of
patients, whereas no effect was observed for the CYP2D6
genotype.28 Furthermore, a potential role of gene variants in
CYP2C19 (*1; *2; *17) and P-glycoprotein (ABCB1;
rs1128503), an efflux transporter of the ATP binding cassette (ABC) family, on clozapine exposure has been
reported, but metabolic side effects were not explored.29
There are no studies in a Caucasian population that specifically investigate both the pharmacokinetic and pharmacodynamic genetic factors contributing to the metabolic side
effects of clozapine in addition to clozapine trough concentration as well as important clinical confounders. Therefore,
this exploratory study was conducted in a cohort of patients
prescribed clozapine as a part of standard patient care, to
more fully address the above gap in knowledge.

Materials and Methods
Patients and Study Design
This was a cross-sectional study of adult patients (aged
18-65 years) with a psychotic disorder (schizophrenia, schizoaffective disorder, or delusional disorder), under the care
of the Prevention and Early Intervention Program for Psychoses (PEPP), London, Canada, who were on stable clozapine therapy for at least 6 months. The study was conducted
between June 2012 and May 2014. Exclusion criteria were
serious uncontrolled illness, nonadherence with medication
(confirmed by the patient or blood clozapine levels after
recruitment), and/or organic psychosis. Meeting the above
inclusion criteria, 60 patients were recruited for this study
after providing written informed consent. Information on
diagnosis, medications prescribed in the previous year, age,
sex, ethnicity, waist circumference, body mass index (BMI),
blood pressure (BP), blood sugar, glycosylated haemoglobin
(HbA1c) if diabetic, lipid profile (including total cholesterol,
high-density lipoprotein [HDL] cholesterol, low-density
lipoprotein [LDL] cholesterol, and triglycerides), smoking
status, and family history of diabetes and CVD was collected. Patients on clozapine under the care of the PEPP
routinely undergo 6-monthly assessment of physical health,
including the above parameters, as well as estimation of
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plasma levels of clozapine and norclozapine. For purposes
of this study, at the time of their routine blood work, an extra
sample of blood was collected for genetic testing. This study
was approved by the Research Ethics Board of the Western
University (London, Ontario).

Drug-Level Analysis
Drug-level analysis was performed as part of the therapeutic
drug monitoring for patients by a clinical laboratory. Time of
last dose and time of blood withdrawal are not routinely
recorded for patients, and thus hours after the last clozapine
dose are unknown, but the majority of patients (87%) were
reported to take clozapine once daily at bedtime, and blood
was taken the following day at their clinic visit, suggesting
>12 hours postdose. Clozapine and norclozapine plasma
concentrations were measured by liquid chromatography–
mass spectrometry (LC-MS). Plasma aliquots were precipitated with phosphate buffer (pH 7) and organic solvent
containing the internal standard (d8-clozapine), then evaporated to dryness and reconstituted in injection buffer (15%
methanol in ammonium formate buffer, pH 3) for analysis by
LC-MS (Agilent 1100 Series; Agilent, Santa Clara, CA,
USA). The single quadruple LC-MS was equipped with a
Phenomenex Kinetex (Torrance, CA, USA) column (50  3
mm, 5 micron). Analytes were separated using the mobile
phase (38% methanol in 25 mM ammonium formate buffer,
pH3) at 0.9 mL/min. Typical between-day coefficients of
variation for the analysis were in the range of 3% for clozapine and 6% for norclozapine.

Genotyping
The single-nucleotide polymorphisms (SNPs) of the most
functionally relevant genes were selected on the basis of
their potential linkage to clozapine metabolism and its metabolic side effects shown in previous studies as well as
reported allelic frequency >5% (see Table 1 and www.cypal
leles.ki.se). Genetic analysis was conducted to determine
SNPs of the drug-metabolizing enzymes CYP1A2
(rs762551, rs2069514, rs35694136) and CYP2C19
(rs4244285, rs12248560), the drug transporter P-glycoprotein/ABCB1 (rs1128503), central serotonin receptor HTR2C
(rs3813929, rs3813928, rs1414334), and LEP (rs7799039)
and LEPR (rs1137101). A CYP2C19 intermediate metabolizer (IM) was defined by a CYP2C19*1/*2 or *17/*2 genotype, a poor metabolizer (PM) by a CYP2C19*2/*2
genotype, an ultrarapid metabolizer (UM) by a
CYP2C19*17/*17 genotype, and an extensive metabolizer
(EM) in the absence of *2 and *3 variant alleles (*1/*1
genotype or wildtype) or a *1/*17 genotype. Genomic DNA
was isolated from venous blood samples with the Gentra
Puregene extraction kit (Qiagen, Alameda, CA, USA) and
concentration determined by PicoGreen (Invitrogen, Carlsbad, CA, USA). Genotyping was performed by TaqMan
Assays (Applied Biosystems, Carlsbad, CA, USA) using a
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Table 1. Allelic Frequency of Single-Nucleotide Polymorphisms (SNPs) of Candidate Genes Analysed (n ¼ 60).
SNP, Reference Allele>Variant Allele
CYP2C19*2 c.681 G>A
CYP2C19*17 g.-806 C>T
ABCB1 c.3435 C>T
CYP1A2*1F g.-163 C>Aa
CYP1A2*1C,*1 L g.-3860 G>A
CYP1A2*1D g.-2467 T>delT
HTR2C g.-759 C>T
HTR2C c.551-3008 C>Gb
HTR2C g.-997 G>A
LEPR c.668 A>G
LEP –2548 G>A

rs Number
rs4244285
rs12248560
rs1128503
rs762551
rs2069514
rs35694136
rs3813929
rs1414334
rs3813928
rs1137101
rs7799039

Reference Allele, n (%)
102/120
99/120
61/120
36/120
116/120
114/120
99/120
25/120
99/120
61/120
72/120

(85.0)
(82.5)
(50.8)
(30.0)
(96.7)
(95.0)
(82.5)
(20.8)
(82.5)
(50.8)
(60.0)

Variant/Functional Allele, n (%)
18/120 (15.0)
21/120 (17.5)
59/120 (49.2)
84/120 (70.0)
4/120 (3.3)
6/120 (5.0)
21/120 (17.5)
95/120 (79.2)
21/120 (17.5)
59/120 (49.2)
48/120 (40.0)

CYP2C19*1 and CYP1A2*1A alleles are considered reference alleles (also wild-type) encoding enzymes with normal function according to the Human
Cytochrome P450 (CYP) Allele Nomenclature Database (www.cypalleles.ki.se).
a
CYP1A2*1F A, the major allele for this single-nucleotide polymorphism (SNP), has been defined as the variant allele according to www.cypalleles.ki.se.
b
HTR2C c.551-3008 G, the major allele for this SNP, has been defined as the variant/functional allele in this study.

7500 Real-time PCR system (Applied Biosystems). HardyWeinberg equilibrium (HWE) was tested using the w2
method. All genotypes were in Hardy-Weinberg equilibrium
with the exception of HTR2C rs3813929 (P < 0.001),
rs3813928 (P < 0.001), and rs1414334 (P < 0.001).

Statistical Analysis
Statistical analysis was performed using the statistical software R30 and GraphPad Prism (V5.02; GraphPad Software,
La Jolla, CA, USA). Differences in clozapine concentration,
dose-normalized concentration, parent-to-metabolite ratio,
and clinical variables were analyzed by Kruskal-Wallis test
and Dunn’s multiple-comparisons test or Mann-Whitney
test, as appropriate. Descriptive statistics were used to summarize patient characteristics. Allelic, additive, dominant,
and recessive models were considered for each SNP and the
genetic model that best describes the outcomes in linear
regression models chosen. Multivariable linear regression
models were used to evaluate the association of SNPs with
drug concentration and metabolic side effects (BMI, blood
sugar, and lipids) after log transformation, controlling for the
confounding factors age, sex, concurrent medication with
known effects on weight increase (quetiapine, valproate,
lithium, risperidone, and olanzapine), smoking status, personal and family history of diabetes, and CVD. Ethnicity was
not a significant covariate in any model and thus has been
omitted in our analyses. We also tested for associations with
metabolic syndrome (diagnosed when individuals have high
waist circumference with 2 or more abnormal parameters
including triglycerides, HDL cholesterol, blood pressure,
and fasting glucose) defined by Adult Treatment Panel
(ATP) III criteria (American Heart Association) using multivariable logistic regression models.31 Adjustment of the significance threshold for multiple testing of the 11 SNPs
genotyped was not applied due to the exploratory character
of this pilot study. We used a statistical significance level of

0.05 for testing; however, we thought it was worth reporting
P values close to 0.05 as these are marginally significant.

Results
The sample included patients with schizophrenia (n ¼ 46)
and schizoaffective (n ¼ 13) and delusional disorders (n ¼
1). The majority of subjects were Caucasian (93%); the
remainder were Asians (n ¼ 2) and First Nations (n ¼ 2).
Thirty percent of patients were on clozapine monotherapy.
Antipsychotic medications were co-prescribed in 61.9% of
patients (olanzapine, risperidone, aripiprazole, ziprasidone,
quetiapine, lurasidone, or asenapine), 21.4% were on a mood
stabilizer (valproate, lithium, carbamazepine), and 14.3%
were taking antidepressants (sertraline, paroxetine, venlafaxine, fluoxetine, citalopram, and escitalopram). Table 2 summarizes the clinical characteristics of patients and their
distribution among those with and without metabolic syndrome; in particular, 52% of the patients had metabolic syndrome, 51% were obese (BMI >30), and an additional 30%
were overweight (BMI 25-30). The observed allelic frequencies for genetic markers as presented in Table 1 are similar to
those previously reported in white populations.

Determinants of Metabolic Side Effects Associated
with Clozapine Therapy
Metabolic syndrome as well as known predictors of metabolic syndrome such as BMI, lipids, and fasting glucose
levels were evaluated as clinically relevant metabolic side
effects. Genetic and clinical determinants of BMI are summarized in Table 3. LEP –2548 G>A, LEPR c.668 A>G, and
–HTR2C c.551-3008 C>G were identified as genetic predictors of BMI and explained, together with concurrent medications known to increase BMI, 30.5% of the observed
variability (Table 3). BMI decreased with increasing number
of variant alleles in these 3 genes, LEP –2548 A, LEPR c.668
G, and HTR2C c.551-3008 G (P ¼ 0.0479; Figure 1A).
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Table 2. Clinical Characteristics of Patients and Their Distribution among Those with and without Metabolic Syndrome.
All Patients (n ¼ 60)

Metabolic Syndrome
Present (n ¼ 31)

Metabolic Syndrome
Absent (n ¼ 28)a

Test for Equality,
P Value

Male
47 (78)
27 (87)
20 (71)
Age, y
36.5 + 11.3 (20-71)
35.4 + 10.1 (20-56)
37.43 + 12.7 (20-71)
Central obesityb
37/55 (67.3)
31/31 (100.0)
6/24 (25.0)
BMI
30.65 + 6.2 (22-56.9)
33.15 + 5.6 (25.7-56.9)
27.87 + 5.7 (22.0-43.4)
BMI 25 or <30, overweight
18/59 (30.5)
9/31 (29.0)
9/28 (32.1)
BMI 30, obese
30/59 (51.0)
22/31 (71.0)
8/28 (28.6)
Hypertensive (being treated
3/57 (5.3)
2/31 (6.5)
1/27 (3.7)
for hypertension)
Diabetic (type II)
6/60 (10.0)
4/31 (12.9)
2/27 (7.1)
Glucose, fasting, mmol/L
5.67 + 0.83 (4.4-10)
5.87 + 0.99 (4.8-10)
5.44 + 0.54 (4.4-6.8)
Systolic blood pressure, mm
117.1 + 14.47 (80-160)
119.2 + 12.13 (92-144)
114.7 + 16.6 (80-160)
Hg
Diastolic blood pressure, mm
77.21 + 9.5 (56-100)
79.1 + 8.2 (64-94)
75.19 + 10.4 (56-100)
Hg
High triglycerides, 1.7 mmol/
42/60 (70.0)
30/31 (96.8)
11/28 (39.3)
L
42/60 (70.0)
30/31 (96.8)
11/28 (39.3)
Low HDLc
Family history of CVD or
38/51 (74.5)
27/27 (100.0)
18/22 (82.0)
diabetes
Smoker
21/60 (35.0)
12/31 (38.7)
9/28 (32.1)
Clozapine dose, mg
333.75 + 131.55 (50-600) 364.5 + 116.1 (150-550) 304.5 + 142.1 (50-600)
Clozapine level, ng/mL
1613.57 + 976.05 (167-3966) 1886.0 + 894.5 (578- 1282.9 + 984.7 (167-3966)
3737)
Norclozapine level, ng/mL
964.60 + 569.43 (53-2600)
1149.8 + 485.6 (303747.5 + 595.1 (53-2600)
2261)
22
10
12
No. of patients receiving
concurrent medications
known to increase weight

0.242
0.509
<0.001
0.001
1.00
0.003
1.00
0.800
0.040
0.257
0.127
<0.001
<0.001
0.074
0.799
0.083
0.017
0.007
1.00

Data are presented as number (%) or mean + standard deviation (range). Two-sample t test was performed for continuous variables and w2 test for
comparing proportions. Since data for a few patients were missing, the percentages calculated in the table are based on the sample for which data were
available. BMI, body mass index; CVD, cardiovascular disease; HDL, high-density lipoprotein.
a
In 1 patient, data needed to calculate the presence of metabolic syndrome were missing, so the data for that participant are not included under the columns of
metabolic syndrome present or absent.
b
Waist circumference >40 inches in males and >35 inches in females.
c
Males, <1.0 mmol/L; females, <1.2 mmol/L.

Table 3. Genetic and Clinical Determinants of BMI: Linear Regression Model Coefficients from Prospective Cohort of 60 Patients
Prescribed Clozapine.
All Patients

Males Only

Variable

Effect (B)

P Value

Effect (B)

P Value

LEP g. –2548 G/A
LEP g. –2548 A/A
LEPR c.668 A/G
LEPR c.668 G/G
HTR2C c.551-3008 C/G
HTR2C c.551-3008 G/G
Concomitant medications known to increase BMI
Adjusted R2

–0.138
–0.0022
–0.143
–0.156
–0.185
–0.089
0.104

0.0552
0.976
0.0081**
0.0262*
0.0676
0.1558
0.0098**
0.305

–0.220
0.0731
–0.1601
–0.1756
–0.2763
–0.0891
0.1206

0.0128*
0.3868
0.0069**
0.0189*
0.0406*
0.1736
0.0085**
0.297

All outcome variables were log transformed for analyses and models adjusted for sex and age. Covariates considered included smoking, family history of
cardiovascular disease and diabetes, diagnosis of diabetes or cardiovascular disease, concurrent medications reported to increase body mass index (BMI),
clozapine dose and clozapine blood level, and genetic markers in CYP1A2, CYP2C19, ABCB1, HTR2C, LEPR, and LEP genes.
*P < 0.05. **P < 0.01.
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Table 4. Genetic and Clinical Determinants of Metabolic Syndrome: Logistic Regression Model Coefficients from Prospective
Cohort of Patients Prescribed Clozapine (n ¼ 59).
Effect Size
Variable

Effect (B)

P Value

Smoking
Clozapine level
CYP2C19*2
CYP1A2*1F A/A
LEPR c.668 A/G
LEPR c.668 G/G
Smoker: CYP1A2*1FA/A

–0.3745
0.00106
–1.5919
–2.507
–2.594
–3.028
4.0318

0.750
0.0148*
0.033*
0.0213*
0.0252*
0.0204*
0.0188*

Adjusted for sex and age. Covariates considered included smoking, family
history of cardiovascular disease and diabetes, diagnosis of diabetes or
cardiovascular disease, concurrent medications reported to increase body
mass index, clozapine dose and clozapine blood level, and genetic markers in
CYP1A2, CYP2C19, ABCB1, HTR2C, LEPR, and LEP genes.
*P < 0.05.

Figure 1. Effect of genetic variation, clinical factors, and clozapine
exposure on BMI and metabolic syndrome. (A) Cumulative effect of
variant alleles, including LEP –2548 A, LEPR c.668 G, and HTR2C
c.551-3008 G on BMI. (B) Effect of concurrent medications known
to increase BMI. (C) Clozapine blood levels in patients with or
without metabolic syndrome. Statistical analyses were performed
with Kruskal-Wallis test with Dunn’s multiple-comparison or
Mann-Whitney test as appropriate. BMI, body mass index; HTR2C,
serotonin receptor; LEP, leptin; LEPR, leptin receptor.

Concurrent medications known to increase BMI resulted in a
1.11-fold difference in BMI compared to patients who did
not take these medications (32.7 vs. 29.4, respectively; Figure 1B). Clozapine dose and blood level were not associated
with BMI (Table 3).
Metabolic syndrome was found to be associated with
the presence of at least 1 CYP2C19*2 allele (P ¼ 0.033)
and the LEPR c.668 A/G (P ¼ 0.0252) and G/G (P ¼
0.0204) genotypes, which resulted in a 80%, 92.5%, and
95.2% lower odds, respectively, compared to their reference genotypes as indicated by logistic regression analysis
(Table 4). Also, a significant interaction was observed
between smoking and CYP1A2 *1F A/A carrier status
(P ¼ 0.028). Our findings suggest that clozapine-treated
smokers with the CYP1A2*1F A/A genotype have a
4.6 times higher odds for metabolic syndrome, whereas
nonsmokers with CYP1A2*1F A/A have an about 92%
lower odds compared to CYP1A2 C/C carriers. Importantly, clozapine blood level was significantly associated
with a higher risk for metabolic syndrome, with an 11%
increase in the odds per 100 ng/mL (Table 4). Clozapine
blood levels in patients with metabolic syndrome were
about 1.5 times higher compared to those without metabolic syndrome (1886.0 + 894.5 vs. 1282.9 + 984.7, P ¼
0.0097; Figure 1C). Aside from known demographic and
clinical predictors of lipids or fasting glucose, no association was found for the genetic variants studied here (data
not shown).

Determinants of Clozapine Exposure
Clozapine plasma level was highly correlated with norclozapine level (r ¼ 0.873) (Figure 2A). Patients with
2 CYP2C19*2 alleles (poor metabolizer [PM] phenotype;
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Figure 2. Characteristics of systemic drug exposure in patients prescribed clozapine (n ¼ 60). (A) Spearman correlation between clozapine
and norclozapine drug level. (B) Effect of CYP2C19 phenotype and (C) smoking status on dose-normalized clozapine levels and clozapine to
norclozapine ratio. Statistical analyses were performed with Kruskal-Wallis test with Dunn’s multiple-comparison or Mann-Whitney test as
appropriate. EM, extensive metabolizer; IM, intermediate metabolizer; PM, poor metabolizer; UM, ultrarapid metabolizer.
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Table 5. Genetic and Clinical Determinants of Blood Clozapine
Concentration: Linear Regression Model Coefficients from Prospective Cohort of Patients Prescribed Clozapine.
Variable
Log(BMI)
Smoking
CYP2C19 IM
CYP2C19 PM
CYP1A2*1F C/A
CYP1A2*1F A/A
Smoker: CYP1A2*1F C/A
Smoker: CYP1A2*1F A/A
Adjusted R2

Coefficient

P Value

1.221
0.676
0.069
0.733
1.023
0.751
–1.372
–0.799

0.0240*
0.268
0.734
0.0579
0.0746
0.187
0.0499*
0.230
0.352

Outcomes were log transformed. Model adjusted for sex, age, and dose.
Clozapine dose, as expected, was a significant determinant of the clozapine
level in this model (P ¼ 0.0004). Covariates considered included smoking,
body mass index (BMI) (for level), and CYP1A2, CYP2C19, and ABCB1 genotypes. CYP1A2*1C (coefficient ¼ 0.637, P ¼ 0.272), CYP1A2*1D (coefficient
¼ –0.099, P ¼ 0.830), and ABCB1 c.3435 (coefficient ¼ 0.142, P ¼ 0.286)
were not significant in our final model. CYP1A2*1F is represented by the
more common A allele. The CYP2C19*1/*2 (n ¼ 10) or *17/*2 (n ¼ 2)
genotype was combined as the CYP2C19 IM phenotype (intermediate
metabolizer), *2/*2 (n ¼ 3) as the CYP2C19 PM phenotype (poor metabolizer), and compared to *1/*1 (n ¼ 27), *1/*17 (n ¼ 17) as the CYP2C19 EM
phenotype (extensive metabolizer). One patient with CYP2C19*17/*17 (UM
or ultrarapid metabolizer) was added to the EM group. CYP2C19*1 denotes
the reference or also wild-type allele, encoding an enzyme with normal
function in a subject with the *1/*1 genotype.
*P < 0.05.

Figure 2B) showed a trend to higher dose-normalized clozapine concentration (P ¼ 0.1056) and a significantly
increased clozapine to norclozapine ratio (P ¼ 0.0237), suggesting enhanced systemic exposure due to impaired clozapine metabolism. No significant differences were observed
for CYP1A2 or ABCB1 genotypes (data not shown). In addition, smokers had a lower clozapine concentration (P ¼
0.064, marginally significant) and metabolic ratio (P ¼
0.044) compared to nonsmokers (Figure 2C), suggesting
induction of CYP1A2 metabolism by smoking.
Multivariable linear regression analysis confirmed
CYP2C19 genotype as a major determinant of clozapine
level after adjustment of other covariates, indicating that
CYP2C19 PM status is associated with higher blood level
(Table 5). Furthermore, a significant interaction was
observed between smoking and CYP1A2*1F g.-163 C/A carrier status (P ¼ 0.0499). Compared to non-CYP1A2*1F carriers (C/C genotype), the presence of 1 CYP1A2*1F A risk
allele resulted in a 0.71 times lower clozapine level among
smokers while enhancing exposure among nonsmokers
2.8-fold. The interaction between smoking and CYP1A2
g.-163 A/A carrier status was not significant (Table 5).
After adjustment for age and sex, CYP2C19 genotype,
CYP1A2*1F-smoking interaction, clozapine dose, and BMI
explained 35.2% of the observed variability in clozapine
blood level in our final model. Previously reported predictors
of clozapine exposure such as CYP1A2 and ABCB1 genotype
were not significantly associated with clozapine level in this
model (Table 5). Assessment of clozapine to norclozapine

ratio by multiple linear regression further supported a role of
CYP2C19*2 genotype (P ¼ 0.027) and smoking (P ¼ 0.052,
marginally significant).

Discussion
This study examined the prevalence and pharmacokinetic
and pharmacodynamic genetic risk factors associated with
clozapine-induced metabolic side effects in a cohort of 60
patients who were prescribed clozapine for a minimum of
6 months, taking into account drug exposure as well as other
potential confounders such as concurrent medications
known to increase body weight as well as smoking. Our
findings show that about two-thirds of the patients on clozapine were overweight or obese and had abnormal triglycerides and HDL cholesterol, with about half of the patients
having metabolic syndrome. These results are similar to
those reported by others.11 One important finding that merits
discussion is the high prevalence of antipsychotic polypharmacy (61.9%) with clozapine. The evidence-based report of
the Canadian Agency for Drugs and Technologies in Health
(CADTH) clearly indicated that high-dose or combination
antipsychotic strategies are not known to be more effective
and may be more harmful.32 Our study confirms that concurrent use of medications known to increase BMI significantly contributed to the increased BMI in patients on
clozapine. The ‘Choosing Wisely Canada’ guidelines for
psychiatry encourages physicians to not routinely prescribe
high-dose or combination antipsychotic treatment strategies
in the treatment of schizophrenia.33
With respect to genetic markers, in our study, 3 SNPs
related to leptin and serotonin signalling were identified as
key genetic predictors of BMI: LEP –2548 G>A, LEPR
c.668 A>G, and HTR2C c.551-3008 C>G. An increasing
number of variant alleles in these 3 genes were associated
with decreased BMI, suggesting a protective effect. Previous
cross-sectional and longitudinal studies have assessed the
relationship of HTR2C, LEP, and LEPR polymorphisms with
metabolic outcomes in psychiatric patients receiving antipsychotic medications, but the evidence remains equivocal,12,34 likely due to differences in study design, treatment
duration, sex, and assessed confounders. Our findings are
consistent with previous studies in patients on olanzapine
or clozapine that support associations between the LEP –
2548 G allele and increase in weight or BMI.35-40 Only 2
other studies,41,42 one in an Asian population and the other in
children and adolescents, reported that the LEP-2548 A
allele was associated with weight gain, but participants in
those studies received risperidone or antipsychotic medications other than olanzapine or clozapine, suggesting that
clozapine and olanzapine may share a unique mechanism
of causing weight gain compared to other atypical antipsychotic medications.43,44 Previously, a significant interaction
between HTR2C and LEP variants with respect to obesity
and metabolic syndrome has been reported.35,40 Yevtushenko et al.35 showed that among patients (n ¼ 134, on
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olanzapine, clozapine, and risperidone) with the HTR2C –
759C/CC genotype, those with the LEP –2548G allele had a
higher BMI, larger waist circumference, and presence of
metabolic syndrome compared to AA carriers. Another
study showed that the combined absence of the HTR2C T
allele and presence of the LEP-2548 G allele was associated
with obesity in patients on atypical antipsychotic
medications.40
Previously, associations of LEPR c.668A>G (Q223 R;
rs1137101) with weight gain or BMI also have been shown
but only when sex or LEP variants are taken into consideration.19,36 Gregoor et al.19 observed that female carriers of
LEPR 223QQ had higher rates of obesity compared to R
carriers in a cross-sectional study of 200 patients (67% male)
on different antipsychotic medications, including clozapine,
olanzapine, and risperidone. A small prospective study
reported a significant interaction between the G alleles of
LEPR and LEP genes and greater weight gain at higher
serum concentrations of olanzapine.36 In contrast, another
cross-sectional study in patients prescribed clozapine (n ¼
56, 78% males) did not find an association between LEP
and LEPR variants and frequency of metabolic syndrome or
obesity when comparing LEP-2548 G/G versus A allele
carriers and LEPR 223 Q/Q versus R allele carriers, but
LEPR 223Q/Q predicted lower triglyceride levels in males
after controlling for dose.45 Similarly, 2 other studies46,47
found no associations between LEPR variants and change
in BMI or weight gain or waist circumference, but the
assessed populations were on multiple antipsychotic medications, including clozapine46 or excluding clozapine.47
Since the sample in our study consisted of predominantly
male patients, it is difficult to draw any conclusions regarding the effect of sex on the association of LEP or LEPR
polymorphism with BMI (Table 3).
In our study, metabolic syndrome was found to be associated with the presence of at least 1 CYP2C19*2 allele and
the LEPR c.668 A/G and G/G genotypes, which resulted in a
80%, 92.5%, and 95.2% lower odds, respectively, compared
to their reference genotypes as indicated by logistic regression analysis. In addition, clozapine blood level significantly
predicted a higher risk for metabolic syndrome. Since there
was a clear association of clozapine level with increased risk,
the negative correlation of CYP2C19 PM status with a lower
odds for metabolic syndrome remains difficult to explain.
However, CYP1A2 has been reported as the main metabolic
pathway for clozapine, and thus additional metabolic effects
mediated by CYP1A2 that were not captured with the evaluated genotypes may play a role.27,29
An association of clozapine level with metabolic side
effects, including BMI, insulin resistance, and glucose and
lipid levels, has been reported in 2 previous studies. In 17
clozapine-treated patients, Melkersson et al.28 found that
higher serum clozapine concentration was linked with a
higher risk of developing insulin and lipid elevation on a
given dose of clozapine. Similarly, in a retrospective survey of 100 patients on clozapine, increased drug exposure
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in women was associated with a higher BMI and glucose
concentration.48 Taken together, these finding suggest that
clozapine plasma level, rather than dose, may be a suitable
tool to monitor the risk of metabolic side effects associated
with clozapine.
Although we observed a linear relationship between clozapine level and prescribed dose (r ¼ 0.4055, P ¼ 0.0013),
clozapine level was highly variable among patients, supporting previous reports.49 Clinical and genetic factors
identified in our study explained 35% of the observed variability. Our findings confirm the role of CYP2C19 polymorphism in the pharmacokinetics of clozapine as
previously shown by in vitro and in vivo studies.26,29 After
controlling for other covariates, CYP2C19 PM status was
found to be associated with higher blood level of clozapine.
In contrast to previous reports, CYP1A2 and ABCB1 genotype as well as smoking were not found to be significantly
associated with clozapine level in our study.12,28,50 However, a significant interaction was observed between smoking and CYP1A2*1F g.-163 CA carrier status. CYP1A2 AA
genotype is thought to enhance inducibility and therefore
increased enzymatic activity,51,52 and smoking is a known
inducer of CYP1A2.29,53,54 This may explain the observed
lower clozapine exposure among smokers carrying the
CYP1A2*1F polymorphism.51,52 However, there are conflicting reports on the influence of CYP1A2*1F polymorphism on clozapine blood levels.51,52,55,56
To our knowledge, this is the first study in a primarily
Caucasian population that specifically targeted clozapine to
investigate the genetic factors in both drug metabolism and
response contributing to its metabolic side effects, taking
into account clozapine blood concentration as well as important confounders. Many previously reported studies lack
information regarding treatment duration, dose, or concomitant medications or simultaneously assess multiple atypical
antipsychotics, thus making it difficult to interpret results.
Patients in our study were enrolled after at least 6 months of
clozapine therapy, and prescribed dose and blood level were
obtained. The detailed data collected here helped control for
the majority of the clinical confounding factors affecting
metabolic outcomes, including age, sex, concurrent medications with known effects on weight increase, smoking status,
personal and family history of diabetes, and CVD. We also
examined the effects of genetic polymorphisms on other
metabolic parameters, including glucose and lipid profile.
Limitations of our study include its cross-sectional nature
and a relatively small sample size, which made it difficult to
analyze sex differences or effects of more rare genotypes
such as CYP1A2*1C and *1D. Many previous studies have
similar patient numbers ranging from 37 to 74 subjects, with
more than two-thirds being males.36,37,39,42,45 Absence of a
patient control group not prescribed clozapine made it difficult to account for the contributory effects of other concomitant atypical antipsychotics on BMI and metabolic
syndrome, but this was in part overcome by including concurrent medications with known effects on weight gain in the
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applied regression model. We did not collect data on severity
of symptoms, which may influence medication adherence
and hence plasma levels of clozapine. Genotype distribution
in a disease population (i.e., schizophrenia) may differ from
the general population, leading to deviation of HWE as
observed for the 3 assessed HTR2C SNPs. Although we have
to use caution if SNPs violating HWE are included in the
analyses because they might result in spurious results, they
can be truly important SNPs hovering in the disease population and associating with outcome of interest.
In conclusion, this exploratory study confirms the high
prevalence of metabolic side effects in patients on clozapine,
with higher clozapine plasma levels being an important risk
factor for metabolic syndrome. Pharmacogenetic markers in
genes encoding CYP2C19, leptin, leptin receptor, and
HTR2C receptor were identified as main predictors of metabolic syndrome as well as BMI. Clinicians should be aware
of potentially increasing a patient’s risk when co-prescribing
antipsychotic medications with clozapine and use clozapine
plasma level to minimize the risk of metabolic syndrome
while titrating the dose to the desired therapeutic effect.
Larger controlled prospective studies are warranted to confirm clinical implications of these findings.
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